Berry Gene (000710.SZ)'s wholly-owned subsidiary and Beijing Children's Hospital signed a cooperation framework agreement to transform project results

Zhitong Finance App News, Berry Gene (000710.SZ) announced that recently, Beijing Berry Hekang Biotechnology Co., Ltd. (“Beijing Berry” or “Party B”), a wholly-owned subsidiary of the company, signed a “Project Achievement Transformation Cooperation Framework Agreement” with Beijing Children's Hospital affiliated to Capital Medical University (“Beijing Children's Hospital” or “Party A” for short).

Whereas, both parties A and B jointly declared the “Capital Clinical Special Diagnosis and Treatment Technology Research and Translational Application” project “Key Technology Research and Product Development for Early Screening and Early Diagnosis of Neonatal Functional Birth Defects” (Project Number: Z221100007422017) commissioned by the Beijing Science and Technology Commission and the Zhongguancun Science and Technology Park Management Committee in November 2022, and undertook the task of transforming the project results. In order to promote the clinical transformation and commercial application of the project results, the two sides reached a cooperation framework agreement based on the principles of equality, mutual benefit, complementary advantages, and collaborative development through friendly negotiations.